Literature DB >> 23776195

Reduced risk of disease during postsecondary dengue virus infections.

Sandra Olkowski1, Brett M Forshey, Amy C Morrison, Claudio Rocha, Stalin Vilcarromero, Eric S Halsey, Tadeusz J Kochel, Thomas W Scott, Steven T Stoddard.   

Abstract

BACKGROUND: Antibodies induced by infection with any 1 of 4 dengue virus (DENV) serotypes (DENV-1-4) may influence the clinical outcome of subsequent heterologous infections. To quantify potential cross-protective effects, we estimated disease risk as a function of DENV infection, using data from longitudinal studies performed from September 2006 through February 2011 in Iquitos, Peru, during periods of DENV-3 and DENV-4 transmission.
METHODS: DENV infections before and during the study period were determined by analysis of serial serum samples with virus neutralization tests. Third and fourth infections were classified as postsecondary infections. Dengue fever cases were detected by door-to-door surveillance for acute febrile illness.
RESULTS: Among susceptible participants, 39% (420/1077) and 53% (1595/2997) seroconverted to DENV-3 and DENV-4, respectively. Disease was detected in 7% of DENV-3 infections and 10% of DENV-4 infections. Disease during postsecondary infections was reduced by 93% for DENV-3 and 64% for DENV-4, compared with primary and secondary infections. Despite lower disease rates, postsecondary infections constituted a significant proportion of apparent infections (14% [for DENV-3 infections], 45% [for DENV-4 infections]).
CONCLUSIONS: Preexisting heterotypic antibodies markedly reduced but did not eliminate the risk of disease in this study population. These results improve understanding of how preinfection history can be associated with dengue outcomes and DENV transmission dynamics.

Entities:  

Keywords:  antibody cross-protection; dengue; dengue fever; seroepidemiology

Mesh:

Substances:

Year:  2013        PMID: 23776195      PMCID: PMC3749012          DOI: 10.1093/infdis/jit273

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  47 in total

Review 1.  Dengue.

Authors:  Cameron P Simmons; Jeremy J Farrar; van Vinh Chau Nguyen; Bridget Wills
Journal:  N Engl J Med       Date:  2012-04-12       Impact factor: 91.245

2.  Epidemiological studies on dengue virus type 3 in Playa municipality, Havana, Cuba, 2001-2002.

Authors:  Maria G Guzman; Angel Alvarez; Susana Vazquez; Mayling Alvarez; Delfina Rosario; Otto Pelaez; Guillermo Cruz; Rosmari Rodriguez; Alequis Pavon; Annia Gonzalez; Luis Morier; Dydie Ruiz; Gustavo Kouri; Scott B Halstead
Journal:  Int J Infect Dis       Date:  2012-01-23       Impact factor: 3.623

Review 3.  Immunity to dengue virus: a tale of original antigenic sin and tropical cytokine storms.

Authors:  Alan L Rothman
Journal:  Nat Rev Immunol       Date:  2011-07-15       Impact factor: 53.106

Review 4.  The pathogenesis of dengue.

Authors:  Jamie Whitehorn; Cameron P Simmons
Journal:  Vaccine       Date:  2011-07-21       Impact factor: 3.641

5.  Interference and facilitation between dengue serotypes in a tetravalent live dengue virus vaccine candidate.

Authors:  Kathryn B Anderson; Robert V Gibbons; Robert Edelman; Kenneth H Eckels; Robert J Putnak; Bruce L Innis; Wellington Sun
Journal:  J Infect Dis       Date:  2011-08-01       Impact factor: 5.226

6.  Dynamics of dengue disease severity determined by the interplay between viral genetics and serotype-specific immunity.

Authors:  Molly OhAinle; Angel Balmaseda; Alexander R Macalalad; Yolanda Tellez; Michael C Zody; Saira Saborío; Andrea Nuñez; Niall J Lennon; Bruce W Birren; Aubree Gordon; Matthew R Henn; Eva Harris
Journal:  Sci Transl Med       Date:  2011-12-21       Impact factor: 17.956

Review 7.  Critical issues in dengue vaccine development.

Authors:  Stephen J Thomas; Timothy P Endy
Journal:  Curr Opin Infect Dis       Date:  2011-10       Impact factor: 4.915

8.  Structural analysis of a dengue cross-reactive antibody complexed with envelope domain III reveals the molecular basis of cross-reactivity.

Authors:  Claire M Midgley; Aleksandra Flanagan; Hai Bac Tran; Wanwisa Dejnirattisai; Kriangkrai Chawansuntati; Amonrat Jumnainsong; Wiyada Wongwiwat; Thaneeya Duangchinda; Juthathip Mongkolsapaya; Jonathan M Grimes; Gavin R Screaton
Journal:  J Immunol       Date:  2012-04-09       Impact factor: 5.422

9.  Spatial dimensions of dengue virus transmission across interepidemic and epidemic periods in Iquitos, Peru (1999-2003).

Authors:  Kelly A Liebman; Steven T Stoddard; Amy C Morrison; Claudio Rocha; Sharon Minnick; Moises Sihuincha; Kevin L Russell; James G Olson; Patrick J Blair; Douglas M Watts; Tadeusz Kochel; Thomas W Scott
Journal:  PLoS Negl Trop Dis       Date:  2012-02-21

10.  Refining the global spatial limits of dengue virus transmission by evidence-based consensus.

Authors:  Oliver J Brady; Peter W Gething; Samir Bhatt; Jane P Messina; John S Brownstein; Anne G Hoen; Catherine L Moyes; Andrew W Farlow; Thomas W Scott; Simon I Hay
Journal:  PLoS Negl Trop Dis       Date:  2012-08-07
View more
  75 in total

1.  Neutralizing antibody titers against dengue virus correlate with protection from symptomatic infection in a longitudinal cohort.

Authors:  Leah C Katzelnick; Magelda Montoya; Lionel Gresh; Angel Balmaseda; Eva Harris
Journal:  Proc Natl Acad Sci U S A       Date:  2016-01-04       Impact factor: 11.205

Review 2.  Which Dengue Vaccine Approach Is the Most Promising, and Should We Be Concerned about Enhanced Disease after Vaccination? The Path to a Dengue Vaccine: Learning from Human Natural Dengue Infection Studies and Vaccine Trials.

Authors:  Aravinda M de Silva; Eva Harris
Journal:  Cold Spring Harb Perspect Biol       Date:  2018-06-01       Impact factor: 10.005

3.  Sequential immunization induces strong and broad immunity against all four dengue virus serotypes.

Authors:  Jue Hou; Shubham Shrivastava; Hooi Linn Loo; Lan Hiong Wong; Eng Eong Ooi; Jianzhu Chen
Journal:  NPJ Vaccines       Date:  2020-07-24       Impact factor: 7.344

4.  Complexity of Neutralizing Antibodies against Multiple Dengue Virus Serotypes after Heterotypic Immunization and Secondary Infection Revealed by In-Depth Analysis of Cross-Reactive Antibodies.

Authors:  Wen-Yang Tsai; Anna Durbin; Jih-Jin Tsai; Szu-Chia Hsieh; Stephen Whitehead; Wei-Kung Wang
Journal:  J Virol       Date:  2015-07       Impact factor: 5.103

5.  Time-varying, serotype-specific force of infection of dengue virus.

Authors:  Robert C Reiner; Steven T Stoddard; Brett M Forshey; Aaron A King; Alicia M Ellis; Alun L Lloyd; Kanya C Long; Claudio Rocha; Stalin Vilcarromero; Helvio Astete; Isabel Bazan; Audrey Lenhart; Gonzalo M Vazquez-Prokopec; Valerie A Paz-Soldan; Philip J McCall; Uriel Kitron; John P Elder; Eric S Halsey; Amy C Morrison; Tadeusz J Kochel; Thomas W Scott
Journal:  Proc Natl Acad Sci U S A       Date:  2014-05-20       Impact factor: 11.205

Review 6.  Historical discourse on the development of the live attenuated tetravalent dengue vaccine candidate TV003/TV005.

Authors:  Anna P Durbin
Journal:  Curr Opin Virol       Date:  2020-10-23       Impact factor: 7.090

Review 7.  Dengue: knowledge gaps, unmet needs, and research priorities.

Authors:  Leah C Katzelnick; Josefina Coloma; Eva Harris
Journal:  Lancet Infect Dis       Date:  2017-02-07       Impact factor: 25.071

Review 8.  The use of longitudinal cohorts for studies of dengue viral pathogenesis and protection.

Authors:  Leah C Katzelnick; Eva Harris
Journal:  Curr Opin Virol       Date:  2018-03-26       Impact factor: 7.090

9.  Preexisting neutralizing antibody responses distinguish clinically inapparent and apparent dengue virus infections in a Sri Lankan pediatric cohort.

Authors:  Kizzmekia S Corbett; Leah Katzelnick; Hasitha Tissera; Ananda Amerasinghe; Aruna Dharshan de Silva; Aravinda M de Silva
Journal:  J Infect Dis       Date:  2014-10-21       Impact factor: 5.226

10.  Characterization of Dengue Virus Infections Among Febrile Children Clinically Diagnosed With a Non-Dengue Illness, Managua, Nicaragua.

Authors:  Jesse J Waggoner; Lionel Gresh; Alisha Mohamed-Hadley; Angel Balmaseda; K James Soda; Janaki Abeynayake; Malaya K Sahoo; Yuanyuan Liu; Guillermina Kuan; Eva Harris; Benjamin A Pinsky
Journal:  J Infect Dis       Date:  2017-06-15       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.